Countermeasure development for rift valley fever: Deletion, modification or targeting of major virulence factor NSs

Future Virology

Volumn 9, Issue 1, 2014, Pages 27-39

  Lihoradova, Olga ^a   Ikegami, Tetsuro ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

MP 12; NSs; Phlebovirus; Rift Valley fever virus; vaccine

Indexed keywords

EID: 84893839975     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.117     Document Type: Review

References (126)

1. Daubney R, Hudson JR. Enzootic hepatitis or Rift Valley fever: an undescribed virus disease of sheep, cattle and man from east Africa. J. Path. Bact. 34, 545-579 (1931).
2. Schmaljohn C, Nichol ST. Bunyaviridae. In: Fields Virology. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (Eds). Lippincott, Williams & Wilkins, PA, USA, 1741-1789 (2007).
3. Meegan JM. The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizzotic and virological studies. Trans. R Soc. Trop. Med. Hyg. 73(6), 618-623 (1979). (Pubitemid 10158921)
4. Shoemaker T, Boulianne C, Vincent MJ, et al. Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg. Infect. Dis. 8(12), 1415-1420 (2002). (Pubitemid 36008778)
5. Balkhy HH, Memish ZA. Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. Int. J. Antimicrob. Agents 21(2), 153-157 (2003). (Pubitemid 36300792)
6. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet. Res. 41(6), 61 (2010).
7. Linthicum KJ, Davies FG, Kairo A, Bailey CL. Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during an inter-epizootic period in Kenya. J. Hyg. (Lond.) 95(1), 197-209 (1985). (Pubitemid 15002982)
8. Swanepoel R, Coetzer JAW. Rift Valley fever. In: Infectious Diseases of Livestock with Special Reference to Southern Africa (2nd Edition). Coetzer JAW, Tustin RC (Eds). Oxford University Press, South Africa, 1037-1070 (2004).
9. Weiss KE. Rift Valley fever-a review. Bull. Epz. Dis. Afr. 5, 431-458 (1957).
10. Easterday BC. Rift Valley fever. Adv Vet Sci, 10, 65-127 (1965).
11. Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234(7), 883-893(2009).
12. Ikegami T, Makino S. The pathogenesis of Rift Valley fever. Viruses 3(5), 493-519 (2011).
13. Schwentker FF, Rivers TM. Rift Valley fever in man: report of a fatal laboratory infection complicated by thrombophlebitis. J. Exp. Med. 59(3), 305-313 (1934).
14. Mundel B, Gear J. Rift Valley fever; I. The occurrence of human cases in Johannesburg. S. Afr. Med. J. 25(44), 797-800 (1951).
15. Sindato C, Karimuribo E, Mboera EG. The epidemiology and socio-economic impact of Rift Valley fever epidemics in Tanzania: a review. Onderstepoort J. Vet. Res. 79(2), e1 (2012).
16. Hartley DM, Rinderknecht JL, Nipp TL, Clarke NP, Snowder GD. Potential effects of Rift Valley fever in the United States. Emerg. Infect. Dis. 17(8), e1 (2011).
17. Department of Agriculture. Part II. 7 CFR Part 331 and 9 CFR Part 121. Agricultural Bioterrorism Protection Act of 2002. Possession, use, and transfer of biological agents and toxins; final rule. Fed. Register 70, 13241-13292 (2005).
18. Shieh WJ, Paddock CD, Lederman E. Pathologic studies on suspect animal and human cases of Rift Valley fever from an outbreak in eastern Africa, 2006-2007. Am. J. Trop. Med. Hyg. 83(2 Suppl.), 38-42 (2010).
19. Ikegami T. Molecular biology and genetic diversity of Rift Valley fever virus. Antiviral Res. 95(3), 293-310 (2012).
20. Euler M, Wang Y, Heidenreich D. Development of a panel of recombinase polymerase amplification assays for detection of biothreat agents. J. Clin. Microbiol. 51(4), 1110-1117(2013).
21. Euler M, Wang Y, Nentwich O, Piepenburg O, Hufert FT, Weidmann M. Recombinase polymerase amplification assay for rapid detection of Rift Valley fever virus. J. Clin. Virol. 54(4), 308-312 (2012).
22. Jansen van Vuren P, Paweska JT. Laboratory safe detection of nucleocapsid protein of Rift Valley fever virus in human and animal specimens by a sandwich ELISA. J. Virol. Methods 157(1), 15-24 (2009).
23. Fukushi S, Nakauchi M, Mizutani T, Saijo M, Kurane I, Morikawa S. Antigen-capture ELISA for the detection of Rift Valley fever virus nucleoprotein using new monoclonal antibodies. J. Virol. Methods 180, 68-74 (2012).
24. Grolla A, Mehedi M, Lindsay R, Bosio C, Duse A, Feldmann H. Enhanced detection of Rift Valley fever virus using molecular assays on whole blood samples. J. Clin. Virol. 54(4), 313-317 (2012).
25. Sall AA, Macondo EA, Sene OK. Use of reverse transcriptase PCR in early diagnosis of Rift Valley fever. Clin. Diagn. Lab. Immunol. 9(3), 713-715 (2002). (Pubitemid 34538237)
26. Paweska JT, Burt FJ, Anthony F. IgGsandwich and IgM-capture enzyme-linked immunosorbent assay for the detection of antibody to Rift Valley fever virus in domestic ruminants. J. Virol. Methods 113(2), 103-112 (2003). (Pubitemid 37205126)
27. Paweska JT, Burt FJ, Swanepoel R. Validation of IgG-sandwich and IgM-capture ELISA for the detection of antibody to Rift Valley fever virus in humans. J. Virol. Methods 124(1-2), 173-181 (2005). (Pubitemid 40138794)
28. Smithburn KC. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br. J. Exp. Pathol. 30(1), 1-16 (1949).
29. WHO. The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/FAO meeting. Bull. World Health Organ. 61(2), 261-268 (1983).
30. Grobbelaar AA, Weyer J, Leman PA, Kemp A, Paweska JT, Swanepoel R. Molecular epidemiology of Rift Valley fever virus. Emerg. Infect. Dis. 17(12), 2270-2276 (2011)
31. Botros B, Omar A, Elian K. Adverse response of nonindigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J. Med. Virol. 78(6), 787-791 (2006).
32. Caplen H, Peters CJ, Bishop DH. Mutagendirected attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66(Pt 10), 2271-2277 (1985). (Pubitemid 15250309)
33. Lokugamage N, Freiberg AN, Morrill JC, Ikegami T. Genetic subpopulations of Rift Valley fever ZH548, MP-12 and recombinant MP-12 strains. J. Virol. 86, 13566-13575 (2012).
34. Rift Valley fever vaccine development, progress and constraints. Proceedings of the GF-TADs meeting, Rome, Italy, January 2011.
35. FAO Animal Production and Health Proceedings, No 12. Food and Agriculture Organization of the United Nations (FAO), Italy (2011).
36. Eddy GA, Peters CJ, Meadors G, Cole FE Jr. Rift Valley fever vaccine for humans. Contr. Epidem. Biostatist. 3, 124-141 (1981).
37. Pittman PR, Liu CT, Cannon TL. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18(1-2), 181-189 (2000). (Pubitemid 29432151)
38. Rusnak JM, Gibbs P, Boudreau E, Clizbe DP, Pittman P. Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. Vaccine 29(17), 3222-3229 (2011).
39. Piper ME, Sorenson DR, Gerrard SR. Efficient cellular release of Rift Valley fever virus requires genomic RNA. PLoS ONE 6(3), e18070 (2011).
40. Lopez N, Muller R, Prehaud C, Bouloy M. The L protein of Rift Valley fever virus can rescue viral ribonucleoproteins and transcribe synthetic genome-like RNA molecules. J. Virol. 69(7), 3972-3979 (1995).
41. Ikegami T, Peters CJ, Makino S. Rift Valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system. J. Virol. 79(9), 5606-5615 (2005). (Pubitemid 40548229)
42. Bouloy M, Janzen C, Vialat P, et al. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs. J. Virol. 75(3), 1371-1377 (2001). (Pubitemid 32094695)
43. Billecocq A, Gauliard N, Le May N, Elliott RM, Flick R, Bouloy M. RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 378(2), 377-384 (2008).
44. Habjan M, Pichlmair A, Elliott RM. NSs protein of Rift Valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J. Virol. 83(9), 4365-4375 (2009).
45. Muller R, Saluzzo JF, Lopez N. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg. 53(4), 405-411 (1995).
46. Ikegami T, Won S, Peters CJ, Makino S. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J. Virol. 80(6), 2933-2940 (2006). (Pubitemid 43346388)
47. Gerrard SR, Nichol ST. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 357(2), 124-133 (2007). (Pubitemid 44821298)
48. Kakach LT, Suzich JA, Collett MS. Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation. Virology 170(2), 505-510 (1989). (Pubitemid 19162564)
49. Kakach LT, Wasmoen TL, Collett MS. Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression. J. Virol. 62(3), 826-833 (1988). (Pubitemid 18068639)
50. Keegan K, Collett MS. Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. J. Virol. 58(2), 263-270 (1986). (Pubitemid 16013616)
51. Dessau M, Modis Y. Crystal structure of glycoprotein C from Rift Valley fever virus. Proc. Natl Acad. Sci. USA 110(5), 1696-1701 (2013).
52. Freiberg AN, Sherman MB, Morais MC, Holbrook MR, Watowich SJ. Threedimensional organization of Rift Valley fever virus revealed by cryoelectron tomography. J. Virol. 82(21), 10341-10348 (2008). (Pubitemid 352691144)
53. Rusu M, Bonneau R, Holbrook MR. An assembly model of Rift Valley fever virus. Front. Microbiol. 3, 254 (2012).
54. Sherman MB, Freiberg AN, Holbrook MR, Watowich SJ. Single-particle cryo-electron microscopy of Rift Valley fever virus. Virology 387(1), 11-15 (2009).
55. Huiskonen JT, Overby AK, Weber F, Grunewald K. Electron cryo-microscopy and single-particle averaging of Rift Valley fever virus: evidence for GN-GC glycoprotein heterodimers. J. Virol. 83(8), 3762-3769 (2009).
56. Won S, Ikegami T, Peters CJ, Makino S. NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture. J. Virol. 80(16), 8274-8278 (2006). (Pubitemid 44182329)
57. Gerrard SR, Bird BH, Albarino CG, Nichol ST. The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology 359(2), 459-465 (2007). (Pubitemid 46274872)
58. Terasaki K, Won S, Makino S. The C-terminal region of Rift Valley fever virus NSm protein targets the protein to the mitochondrial outer membrane and exerts anti-apoptotic function. J. Virol. 87, 676-682 (2013).
59. Won S, Ikegami T, Peters CJ, Makino S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J. Virol. 81(24), 13335-13345 (2007). (Pubitemid 350247830)
60. Struthers JK, Swanepoel R, Shepherd SP. Protein synthesis in Rift Valley fever virus-infected cells. Virology 134(1), 118-124 (1984). (Pubitemid 14138928)
61. Muller R, Poch O, Delarue M, Bishop DH, Bouloy M. Rift Valley fever virus L segment: correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases. J. Gen. Virol. 75 1345-1352 (1994).
62. Morin B, Coutard B, Lelke M. The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. PLoS Pathog. 6(9), e1001038 (2010).
63. Reguera J, Weber F, Cusack S. Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-dependent transcription. PLoS Pathog. 6(9), e1001101 (2010).
64. Lozach PY, Kuhbacher A, Meier R, et al. DC-SIGN as a receptor for phleboviruses. Cell Host Microbe 10(1), 75-88 (2011).
65. Lozach PY, Mancini R, Bitto D, et al. Entry of bunyaviruses into mammalian cells. Cell Host Microbe 7(6), 488-499 (2010).
66. de Boer SM, Kortekaas J, de Haan CA, Rottier PJ, Moormann RJ, Bosch BJ. Heparan sulfate facilitates Rift Valley fever virus entry into the cell. J. Virol. 86(24), 13767-13771 (2012).
67. Harmon B, Schudel BR, Maar D. Rift Valley fever virus strain MP-12 enters mammalian host cells via caveolae-mediated endocytosis. J. Virol. 86, 12954-12970 (2012).
68. Raymond DD, Piper ME, Gerrard SR, Smith JL. Structure of the Rift Valley fever virus nucleocapsid protein reveals another architecture for RNA encapsidation. Proc. Natl Acad. Sci. USA 107(26), 11769-11774 (2010).
69. Ikegami T, Won S, Peters CJ, Makino S. Rift Valley fever virus NSs mRNA is transcribed from an incoming anti-viral-sense S RNA segment. J. Virol. 79(18), 12106-12111 (2005). (Pubitemid 41279329)
70. Gerrard SR, Nichol ST. Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein. J. Virol. 76(23), 12200-12210 (2002). (Pubitemid 35304317)
71. Findlay GM. Rift Valley fever on enzootic hepatitis. Trans. R. Soc. Trop. Med. Hyg. 25, 229-262 (1931).
72. Smith DR, Steele KE, Shamblin J. The pathogenesis of Rift Valley fever virus in the mouse model. Virology 407(2), 256-267 (2010).
73. Gommet C, Billecocq A, Jouvion G. Tissue tropism and target cells of NSs-deleted Rift Valley fever virus in live immunodeficient mice. PLoS Negl. Trop. Dis. 5(12), e1421 (2011).
74. Lihoradova O, Kalveram B, Indran SV, et al. The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine. J. Virol. 86(14), 7650-7661 (2012).
75. Reed C, Steele KE, Honko A, Shamblin J, Hensley LE, Smith DR. Ultrastructural study of Rift Valley fever virus in the mouse model. Virology 431(1-2), 58-70 (2012).
76. Niklasson BS, Meadors GF, Peters CJ. Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters. Acta Pathol. Microbiol. Immunol. Scand. (C) 92(4), 197-200 (1984). (Pubitemid 14023398)
77. Dodd KA, McElroy AK, Jones ME, Nichol ST, Spiropoulou CF. Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses. J. Virol. 87(11), 6161-6171 (2013).
78. Indran SV, Lihoradova OA, Phoenix I. Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains the neuroinvasiveness in mice. J. Gen. Virol. (In Press) (2013).
79. Lihoradova OA, Indran SV, Kalveram B, et al. Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever Sicilian virus. PLoS Negl. Trop. Dis. 7(4), e2181 (2013).
80. Jansen van Vuren P, Tiemessen CT, Paweska JT. Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice. PLoS ONE 6(9), e25027 (2011).
81. Yadani FZ, Kohl A, Prehaud C, Billecocq A, Bouloy M. The carboxy-terminal acidic domain of Rift Valley fever virus NSs protein is essential for the formation of filamentous structures but not for the nuclear localization of the protein. J. Virol. 73(6), 5018-5025 (1999). (Pubitemid 29246763)
82. Billecocq A, Spiegel M, Vialat P, et al. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J. Virol. 78(18), 9798-9806 (2004). (Pubitemid 39187098)
83. Kohl A, di Bartolo V, Bouloy M. The Rift Valley fever virus nonstructural protein NSs is phosphorylated at serine residues located in casein kinase II consensus motifs in the carboxy-terminus. Virology 263(2), 517-525 (1999). (Pubitemid 29521542)
84. Le May N, Dubaele S, Proietti De Santis L, Billecocq A, Bouloy M, Egly JM. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116(4), 541-550 (2004). (Pubitemid 38264431)
85. Le May N, Mansuroglu Z, Leger P, et al. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog. 4(1), e13 (2008).
86. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, Makino S. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog. 5(2), e1000287 (2009).
87. Kalveram B, Lihoradova O, Indran SV, Lokugamage N, Head JA, Ikegami T. Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR. Virology 435, 415-424 (2013).
88. Kalveram B, Lihoradova O, Ikegami T. NSs protein of Rift Valley fever virus promotes post-translational downregulation of the TFIIH subunit p62. J. Virol. 85, 6234-6243 (2011).
89. Verdaasdonk JS, Bloom K. Centromeres: unique chromatin structures that drive chromosome segregation. Nat. Rev. Mol. Cell. Biol. 12(5), 320-332 (2011).
90. Mansuroglu Z, Josse T, Gilleron J, et al. Non structural NSs protein of Rift Valley fever Virus interacts with pericentromeric DNA sequences of the host cell inducing chromosome cohesion and segregation defects. J. Virol. 84, 928-939 (2009).
91. Baer A, Austin D, Narayanan A, et al. Induction of DNA damage signaling upon Rift Valley fever virus infection results in cell cycle arrest and increased viral replication. J. Biol. Chem. 287(10), 7399-7410 (2012).
92. Austin D, Baer A, Lundberg L, et al. p53 activation following Rift Valley fever virus infection contributes to cell death and viral production. PLoS ONE 7(5), e36327 (2012).
93. Benferhat R, Josse T, Albaud B, et al. Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome. J. Virol. 86(20), 11333-11344 (2012).
94. Vaughn VM, Streeter CC, Miller DJ, Gerrard SR. Restriction of Rift Valley fever virus virulence in mosquito cells. Viruses 2(2), 655-675 (2010).
95. Leger P, Lara E, Jagla B, et al. Dicer-2-and Piwi-mediated RNA interference in Rift Valley fever virus-infected mosquito cells. J. Virol. 87(3), 1631-1648 (2013).
96. Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, Bouloy M. Evaluation of the efficacy and safety of the Rift Valley fever Clone 13 vaccine in sheep. Vaccine 28(29), 4581-4587 (2010).
97. von Teichman B, Engelbrecht A, Zulu G, Dungu B, Pardini A, Bouloy M. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 29(34), 5771-5777 (2011).
98. Thiongane Y, Lena P, Moustapha M, et al. Pathogenicity and immunogenicity of the reassortant attenuated strain R566 of Rift Valley fever virus in sheep. Presented at: The FAO/IAEA International Symposium on Applications of Gene-based Technologies for Improving Animal Production and Health in Developing Countries. Austria, 6-10 October 2003.
99. Habjan M, Penski N, Spiegel M, Weber F. T7 RNA polymerase-dependent and-independent systems for cDNA-based rescue of Rift Valley fever virus. J. Gen. Virol. 89(Pt 9), 2157-2166 (2008).
100. Bird BH, Albarino CG, Hartman AL, Erickson BR, Ksiazek TG, Nichol ST. Rift Valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J. Virol. 82(6), 2681-2691 (2008). (Pubitemid 351329159)
101. Bird BH, Maartens LH, Campbell S, et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J. Virol. 85(24), 12901-12909 (2011).
102. Bird BH, Albarino CG, Nichol ST. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 362(1), 10-15 (2007). (Pubitemid 46617699)
103. Crabtree MB, Kent Crockett RJ, Bird BH, et al. Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection. PLoS Negl. Trop. Dis. 6(5), e1639 (2012).
104. McElroy AK, Albarino CG, Nichol ST. Development of a RVFV ELISA that can distinguish infected from vaccinated animals. Virol. J. 6, 125 (2009).
105. Fernandez JC, Billecocq A, Durand JP, et al. The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus. Clin. Vaccine Immunol. 19(1), 5-10 (2012).
106. Faburay B, Wilson W, McVey DS, et al. Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep. Vector Borne Zoonotic Dis. 13(9), 619-629 (2013).
107. Lihoradova O, Ikegami T. Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever. Expert Rev. Vaccines 11(11), 1283-1285 (2012).
108. Matsuno K, Weisend C, Travassos da Rosa AP, et al. Characterization of the Bhanja serogroup viruses (Bunyaviridae): a novel species of the genus Phlebovirus and its relationship with other emerging tick-borne phleboviruses. J. Virol. 87(7), 3719-3728 (2013).
109. Yu XJ, Liang MF, Zhang SY, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N. Engl. J. Med. 364(16), 1523-1532 (2011).
110. Xu F, Chen H, Travassos da Rosa AP, Tesh RB, Xiao SY. Phylogenetic relationships among sandfly fever group viruses (Phlebovirus: Bunyaviridae) based on the small genome segment. J. Gen. Virol. 88(Pt 8), 2312-2319 (2007). (Pubitemid 47194230)
111. Kalveram B, Ikegami T. Toscana virus NSs protein promotes degradation of doublestranded RNA-dependent protein kinase. J. Virol. 87, 3710-3718 (2013).
112. Gori Savellini G, Weber F, Terrosi C, Habjan M, Martorelli B, Cusi MG. Toscana virus induces interferon although its NSs protein reveals antagonistic activity. J. Gen. Virol. 92(Pt 1), 71-79 (2010).
113. Perrone LA, Narayanan K, Worthy M, Peters CJ. The S segment of Punta Toro virus (Bunyaviridae, Phlebovirus) is a major determinant of lethality in the Syrian hamster and codes for a type I interferon antagonist. J. Virol. 81(2), 884-892 (2007). (Pubitemid 46067913)
114. Ikegami T, Makino S. Rift Valley fever vaccines. Vaccine 27(Suppl. 4), D69-D72 (2009).
115. Indran SV, Ikegami T. Novel approaches to develop Rift Valley fever vaccines. Front. Cell. Infect. Microbiol. 2, 131 (2012).
116. Mandell RB, Flick R. Rift Valley fever virus: an unrecognized emerging threat? Hum. Vaccin. 6(7), 597-601 (2010).
117. Kortekaas J, Antonis AF, Kant J, et al. Efficacy of three candidate Rift Valley fever vaccines in sheep. Vaccine 30(23), 3423-3429 (2012).
118. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 11(Suppl. 4), S750-S761 (1989).
119. Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res. 6(5), 285-297 (1986). (Pubitemid 16043762)
120. Kende M, Alving CR, Rill WL, Swartz GM Jr, Canonico PG. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob. Agents Chemother. 27(6), 903-907 (1985). (Pubitemid 15062733)
121. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339(21), 1485-1492 (1998). (Pubitemid 28543496)
122. Dominguez KD, Mercier RC. Treatment of RSV pneumonia in adults-evidence of ribavirin effectiveness? Ann. Pharmacother. 33(6), 739-741 (1999). (Pubitemid 29309734)
123. Knowles SR, Phillips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin. Infect. Dis. 37(8), 1139-1142 (2003). (Pubitemid 37323673)
124. Gowen BB, Bailey KW, Scharton D, et al. Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge. Antiviral Res 98(2), 135-143 (2013)
125. Head JA, Kalveram B, Ikegami T. Functional analysis of Rift Valley fever virus NSs encoding a partial truncation. PLoS ONE 7, e45730 (2012).
126. Narayanan A, Kehn-Hall K, Senina S et al Curcumin inhibits Rift Valley fever virus replication in human cells. J. Biol. Chem. 287(40), 33198-33214 (2012).